Liquid Biopsy for Early Cancer Detection and Monitoring Market Size, Share, Trends, Industry Analysis Report By Biomarker [Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs)], By Cancer, By Technology, By End Use, By Region – Market Forecast, 2

The liquid biopsy for early cancer detection and monitoring market size is expected to reach USD 6.53 billion by 2034, according to a new study by Polaris Market Research. The report “Liquid Biopsy for Early Cancer Detection and Monitoring Market Share, Size, Trends, Industry Analysis Report By Biomarker [Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs)], By Cancer, By Technology, By End Use, By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Liquid biopsy is a noninvasive diagnostic tool that detects cancer-related biomarkers in bodily fluids, primarily blood, to enable early cancer detection and monitoring. Unlike traditional tissue biopsies, which require surgical procedures, liquid biopsies analyze circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, or other cancer-derived molecules released into the bloodstream. This approach offers a less invasive, faster, and repeatable method for identifying genetic mutations, epigenetic changes, and protein signatures associated with tumors. Liquid biopsies are particularly valuable for early cancer detection, as they identify malignancies before symptoms appear or imaging tests reveal tumors. They are also used to monitor treatment response, detect minimal residual disease (MRD), and track tumor evolution in real-time, helping clinicians adjust therapies based on molecular changes.

The usage of liquid biopsies spans various clinical scenarios, including screening high-risk individuals, guiding personalized treatment, and detecting relapse earlier than conventional methods. In lung cancer, liquid biopsies identify EGFR mutations to tailor tyrosine kinase inhibitor therapy. In colorectal cancer, they help monitor KRAS mutations for resistance to treatment. Advancements in next-generation sequencing (NGS) and AI-driven data analysis are enhancing the accuracy and scalability of liquid biopsy.

Liquid Biopsy for Early Cancer Detection and Monitoring Market Report Highlights

In terms of biomarker, the circulating tumor DNA (ctDNA) segment held 32.31% of the revenue share in 2024 due to its high sensitivity, broad applicability across cancer types, and ability to detect minimal residual disease and tumor heterogeneity.

Based on cancer, the lung cancer segment accounted for a major revenue share in 2024 due to the high incidence of the disease, need for early detection, and the limitations of traditional diagnostic methods such as tissue biopsy and imaging.

In terms of technology, the next-generation sequencing (NGS) segment dominated the revenue share in 2024 due to its capability to analyze multiple genetic alterations simultaneously with high sensitivity and specificity.

Based on end use, the diagnostic laboratories segment is projected to grow at a robust pace in the coming years. These laboratories offer specialized expertise, cost-effective testing solutions, and shorter turnaround times, making them attractive for both physicians and patients.

The North America liquid biopsy for early cancer detection and monitoring market accounted for 37.15% of global revenue share in 2024. This dominance is attributed to the high prevalence of cancer, increasing adoption of noninvasive diagnostic techniques, and strong healthcare infrastructure.

A few global key players in the liquid biopsy for early cancer detection and monitoring market include AnchorDx; Burning Rock Biotech Limited; Elypta AB; Exact Sciences Corporation; Freenome Holdings, Inc.; GENECAST; Illumina, Inc.; Guardant Health; Lucence Health Inc.; Myriad Genetics, Inc.; and Oncimmune.

Polaris Market Research has segmented the liquid biopsy for early cancer detection and monitoring market report on the basis of biomarker, cancer, technology, end use, and region:

By Biomarker Outlook (Revenue, USD Billion, 2020–2034)

Circulating Tumor DNA (ctDNA)

Circulating Tumor Cells (CTCs)

Exosomes/Microvesicles

Circulating Proteins

By Cancer Outlook (Revenue, USD Billion, 2020–2034)

Lung Cancer

Breast Cancer

Colorectal Cancer

Prostate Cancer

Others

By Technology Outlook (Revenue, USD Billion, 2020–2034)

Next-Generation Sequencing (NGS)

PCR-based assays

Microarray

Epigenomics / Methylation assays

Others

By End Use Outlook (Revenue, USD Billion, 2020–2034)

Hospitals

Diagnostic Laboratories

Others

By Regional Outlook (Revenue, USD Billion, 2020–2034)

North America

U.S.

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America Show more